31.10.2023 16:45:01 CET | Thor Medical ASA | Non-regulatory press releases

Oslo, 31 October 2023: Thor Medical ASA is an emerging supplier of naturally
occurring radioactive alpha emitters for the global cancer therapy market. To
position the Company for successfully executing on its strategy, Thor Medical is
pleased to introduce the hiring of Astrid Liland and Thor Andre Karlsen to
strengthen Thor Medical's development capabilities.

From January 1 2024, Liland (MSc Nuclear chemistry) will take the position as
EHS manager in Thor Medical. Astrid brings more than 20 years of experience in
scientific environmental and nuclear chemistry, radiation protection,
radioecology, and emergency preparedness from national, Nordic, and
international projects.

She will assume all responsibilities related to radiation protection and safety,
as well as managing relevant regulatory authorities. Astrid comes from the
position as Head of preparedness and emergency at Directorate for Radiation
Protection and Nuclear Safety (DSA).

"With Astrid on board, we will have access to all competence necessary to
establish both laboratories and production facilities in accordance with
existing regulatory requirements," says Alf Bjørseth, CEO of Thor Medical ASA.

From February 1 2024, Karlsen (MSc Environmental chemistry) will take the
position as process engineer in Thor Medical. Thor Andre comes from a position
as process engineer at Ulefos and has previous experience from Jotun.

"With his background in environmental chemistry, and safely and efficiently
operating advanced production facilities, Thor Andre will play a key role in
establishing and operating the pilot production facilities at Herøya," says
Bjørseth.

Thor Medical will continue to develop its organization according to progress of
the Company's business plan and requirements.

CONTACTS

 * Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440,
   brede.ellingseter@thormedical.no 

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

To learn more, visitwww.thormedical.no - https://www.thormedical.no.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/2709/3797/Download%20announcement
%20as%20PDF.pdf